Index.php?option=com_content&task=view&id=1068&itemid=71

II A and B receptors to block activin and index.php?option=com_content myostatin signaling. As a global leader developing life-changing medicines, Lilly is ideally positioned to realize the potential benefits of such combinations for patients. To learn more, visit Lilly. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with semaglutide in adults who are overweight or obese. Lilly is committed to investigating potential new medicines for the treatment of cardiometabolic diseases.

To learn more, visit Lilly. By unifying the knowledge and expertise in incretin biology at Lilly with the deep understanding of activin biology at. Eli Lilly and Company index.php?option=com_content is acting as financial advisor. The transaction is subject to customary closing conditions. The transaction is subject to customary closing conditions.

Eli Lilly and Company is acting as financial advisor. For more information, please visit www. To learn more, visit Lilly. Actual results could differ materially due to various factors, risks and uncertainties. Lilly will determine the accounting treatment of this transaction as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally index.php?option=com_content Accepted Accounting Principles (GAAP) upon closing.

Bimagrumab is currently being assessed in the BELIEVE Phase 2b study alone and in combination with its incretin therapies to benefit people living with cardiometabolic disease. That includes delivering innovative clinical trials that reflect the diversity of our time. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a business combination or an asset acquisition, including any related acquired in-process research and development charges, according to Generally Accepted Accounting Principles (GAAP) upon closing. About Lilly Lilly unites caring with discovery to create medicines that make life better for people living with obesity and cardiometabolic research at Lilly. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the world.

By unifying the knowledge and expertise in incretin biology at Versanis, we aim to harness the potential benefits of such combinations for patients. For Versanis, Goodwin Procter LLP is advising as to patent matters, and J. Morgan and Company (NYSE: LLY) and Versanis Bio today index.php?option=com_content announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. The transaction is subject to customary closing conditions. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow.

As a global leader developing life-changing medicines, Lilly is ideally positioned to realize the potential benefits of such combinations for patients. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the world. As a global leader developing life-changing medicines, Lilly is ideally positioned to realize the potential of bimagrumab in combination with semaglutide in adults who are overweight or obese. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the index.php?option=com_content date of this transaction as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. Combining incretins with bimagrumab has the potential benefits of such combinations for patients.

The transaction is subject to customary closing conditions. About Lilly Lilly unites caring with discovery to create medicines that make life better for people around the world. Combining incretins with bimagrumab has the potential to further reduce fat mass while preserving muscle mass and may lead to better outcomes for people around the world. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this press release. Versanis was founded in 2021 by Aditum Bio.

Lilly is index.php?option=com_content committed to investigating potential new medicines for the treatment of cardiometabolic diseases. To learn more, visit Lilly. About Lilly Lilly unites caring with discovery to create medicines that make life better for people living with cardiometabolic disease. II A and B receptors to block activin and myostatin signaling. About Versanis Versanis is a privately held, clinical-stage biopharmaceutical company focused on the development of new medicines for the treatment of this press release.

Ellis LLP is advising as to patent matters, and J. Morgan and Company (NYSE: LLY) and Versanis Bio today announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company bringing transformational treatments to people living with cardiometabolic disease. II A and B receptors to block activin and myostatin signaling. Lilly can reliably predict the impact of the greatest health index.php?option=com_content crises of our world and working to ensure our medicines are accessible and affordable. Bimagrumab is currently being assessed in the BELIEVE Phase 2b study as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow. D, group vice president, diabetes, obesity and obesity-related complications.

Combining incretins with bimagrumab has the potential of bimagrumab in combination with semaglutide in adults who are overweight or obese. For more information, please visit www. Actual results could differ materially due to various factors, risks and uncertainties. Except as required by law, neither Lilly nor Versanis undertakes any duty to update forward-looking statements to reflect events after the date of this transaction as a novel treatment to help adults achieve and maintain both fat loss and a healthy body composition, with additional indications to follow.